Skip to content
Home page - Centenary Institute Centenary Institute

Primary menu

  • Research
        • Research

          The latest medical research into our most complex health challenges across cancer, cardiovascular disease and inflammation

          Learn more

        • Cancer
        • Inflammation
        • Cardiovascular
        • Programs
        • Laboratories
        • Diseases
        • Expertises
        • Services and instrumentation
  • Support us
        • Support us

          By supporting the Centenary Institute you can help improve human health through excellence in medical research

          Learn more

        • Workplace giving
        • Host or join a fundraiser
        • Gift in your Will
        • Donate in Memory
  • Impact
        • Impact

          Our research develops new diagnostics, treatments and cures for some of the most deadly and debilitating diseases affecting society today

          Learn more

        • Breakthroughs
        • Community and research
        • Real stories
  • Health hub
        • Health hub

          A range of practical information to assist in the possible preventions to disease through evidence-based research on how the body works.

          Learn more

        • Inflammation
        • The Good Gut Anti-Inflammatory Diet
        • Ageing
        • Exercise Snack Program
  • News & events
        • News & Events

          Explore the latest research breakthroughs and ways you can take part in our series of digital and in-person events

        • News
        • Events
        • Media Hub
  • About us
        • About us

          We are world-leading independent medical research institute that drives collaboration to accelerate and translate solutions to our most complex health challenges

          Learn more

        • Governance
        • Corporate information
        • Annual reports
        • Our researchers
        • Careers and studies
        • Contact
  • Donate
    Centenary Institute > News > Safer anti-clotting drugs on the horizon

Safer anti-clotting drugs on the horizon

Date time 29 July, 2018
News Type News type Media release

New findings from a study into blood clots led by scientists at the Centenary Institute, will help researchers to develop safer anti-clotting drugs for patients suffering from thrombosis.

Emerging evidence shows that a family of enzymes (known as oxidoreductases) are released from platelets and blood vessel linings in reaction to injury, and are essential for blood clotting to occur. However, scientists have so far been unable to determine the exact function of these enzymes in this process.

A research paper, published in the peer-reviewed scientific journal eLife, has progressed that understanding by showing how one particular type of oxidoreductase, ERp5, inhibits platelet clumping – thereby hindering blood clotting. It does so by breaking a chemical bond in a key receptor protein (known as an integrin) on the platelet surface.

“Currently patients with thrombosis can be treated with anti-clotting therapeutics that target platelet integrins, but they can also cause life-threatening bleeding as a side effect. Our findings will help us develop safer anti-clotting drugs because we can now modulate integrin function via this chemical bond,” says co-lead author Dr Joyce Chiu, from the ACRF Centenary Cancer Research Centre.

Read the full media release.

Learn more about the work of the ACRF Centenary Cancer Research Centre.

Media enquires

For all media and interview enquiries, please contact Tony Crawshaw, Media and Communications Manager

Phone number Phone Number 0402 770 403

Email Email t.crawshaw@centenary.org.au

Media Release

Download

Recent Stories

  • Metastatic cancer research boosted

    Dr Dannel Yeo from the Centenary Institute and Clinical Associate Professor Kate Mahon from Chris O’Brien Lifehouse, have been awarded an inaugural Sydney Cancer Partners Translational Fellowship.
    News Type: Research News
    Date 03 Mar 2023
  • The Year That Made Me: Professor John Rasko

    Professor John Rasko AO, Head of the Gene and Stem Cell Therapy Program at the Centenary Institute has featured on the popular Radio National show Sunday Extra in the segment called ‘The Year That Made Me’.
    News Type: Media coverage
    Date 21 Feb 2023
  • Top abstract prize for gene therapy research

    Professor John Rasko AO and team have received the top scoring abstract award at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders in Manchester.
    News Type: Research News
    Date 15 Feb 2023
  • Event celebrates ‘The Good Gut Anti-Inflammatory Diet’

    The Centenary Institute has celebrated the publication of a new book, 'The Good Gut Anti-Inflammatory Diet’ at a special event, held at the Dymocks Bookstore, Sydney.
    News Type: Community
    Date 13 Feb 2023

Subscribe to receive news on
research updates and free events

Newsletter

The Centenary Institute is a world-leading independent Medical Research Institute.

We acknowledge the Gadigal of the Eora Nation, the traditional custodians of the Country on which the Centenary Institute stands.

About

  • About
  • Governance
  • Corporate information

Research

  • Programs
  • Our researchers
  • News
  • Media hub

Careers & studies

  • Career opportunities
  • Life at Centenary

Links

  • Contact
  • Privacy statement

Contact us

Building 93, Royal Prince Alfred Hospital
Missenden Rd
Camperdown NSW 2050 Australia
Telephone +61 2 9565 6100
Fax +61 2 9565 6101

Centenary Institute ABN 22 654 201 090 (DGR 1) • Centenary Institute Medical Research Foundation ABN 85 778 244 012 (DGR 2)
© 2017 Centenary Institute of Cancer Medicine and Cell Biology.

  • Linkedin
  • Facebook
  • Twitter
  • Youtube
  • Instagram